Merrill retains Actelion at neutral

Actelion was retained at neutral by Merrill Lynch analyst Erica Whittaker on news that the company posted better-than-expected net revenues due to strong Tracleer sales. However, the company missed Merrill's forecasts and consensus on the bottom line due to higher operating expenses, particularly marketing and advertising costs. Shares of the Allschwil, Switzerland, biopharmaceutical company were down CHF 3.10, or 2.58%, at CHF 117.20 on volume of 431,778 shares versus the three-month running average of 180,906 shares. (Swiss: ATLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.